title: [Personalized medicine in oncology: one drug, one biomarker].
abstract: Sir Williams Osler, the father of Modern Medicine, recognized more than one century ago, that "If it were not for the great variability among individuals, medicine might as well be a science and not an art". Nevertheless today, in our opinion this paradigm is presently in crisis. Clinical medicine starts to be a science thanks to this variability that is generating a personalized medicine based on the concepts of pharmacogenetic and pharmacogenomic. In the Medical Oncology field this era has begun: today the determination of mutations in several given genes such as Her2, KRAS, EGFR, ALK, and BRAF is translating into a individualized strategy that produces benefits that are clearly superior to present indiscriminate therapeutic decisions. This strategy is more active, more safe and also more efficient.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Díaz-Rubio García
mesh_terms: D015415:Biomarkers; D052138:Genes, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D057285:Precision Medicine
chemical_list: D015415:Biomarkers